ANI Brings In Record Revenues As Cortrophin Rollout Ploughs Ahead
Increased Expenses Fail To Knock The Wind From ANI’s Wings
ANI Pharmaceuticals has recorded its highest-ever quarterly revenue of $73.9m during Q2, following the launch of its cortrophin gel and a substantial growth in generics revenue.
